Sec. 302. Surveillance and Testing of Opioids to Prevent Fentanyl Deaths
619 words·~3 min read·
/bill/115/hr/6/ih/section-302A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Part F of title III of the Public Health Service Act ( 42 U.S.C. 262 et seq.) is amended— in the heading of part F, by striking and inserting and clinical laboratories ; and , clinical laboratories, and public health laboratories by adding at the end the following new subpart: The Secretary shall establish a program to award grants to Federal, State, and local agencies to support the establishment or operation of public health laboratories to detect fentanyl, its analogues, and other synthetic opioids, as described in subsection (b).
The Secretary, in consultation with the Director of the National Institute of Standards and Technology, shall— develop standards for safely and effectively handling and testing fentanyl, its analogues, and other synthetic opioids; develop fentanyl and fentanyl analog reference materials and quality control standards and protocols to calibrate instrumentation for clinical diagnostics and postmortem surveillance; and include in the standards developed pursuant to paragraph
(1)procedures for encountering new and emerging synthetic opioid formulations and reporting those findings to other Federal, State, and local public health laboratories. The Secretary shall require grantees under subsection
(a)to— follow the standards established under subsection
(b)and be capable of providing systematic and routine laboratory testing of drugs for the purposes of obtaining and disseminating public health information to Federal, State, and local public health officials, laboratories, and other entities the Secretary deems appropriate; work with law enforcement agencies and public health authorities, as feasible, to develop real-time information on the purity and movement of fentanyl, its analogues, and other synthetic opioids; assist State and local law enforcement agencies in testing seized drugs when State and local forensic laboratories request additional assistance; provide early warning information and advice to Federal, State, and local law enforcement agencies and public health authorities regarding potential significant changes in the supply of fentanyl, its analogues, and other synthetic opioids; provide biosurveillance for non-fatal exposures; and provide diagnostic testing for non-fatal exposures of emergency personnel. To carry out this section, there is authorized to be appropriated $15,000,000 for each of fiscal years 2019 through 2023. . Title III of the Public Health Service Act is amended by inserting after section 317T of such Act ( 42 U.S.C. 247b–22 ) the following new section: The Director of the Centers for Disease Control and Prevention shall enhance its drug surveillance program by— expanding its surveillance program to include all 50 States and the territories of the United States; increasing and accelerating the collection of data on fentanyl, its analogues, and other synthetic opioids and new emerging drugs of abuse, including related overdose data from medical examiners and drug treatment admissions; and utilizing available and emerging information on fentanyl, its analogues, and other synthetic opioids and new emerging drugs of abuse, including information from— the National Drug Early Warning System; State and local public health authorities; and Federal, State, and local public health laboratories. To carry out this section, there is authorized to be appropriated $10,000,000 for each of fiscal years 2019 through 2023. . Part P of title III of the Public Health Service Act ( 42 U.S.C. 280g et seq.) is amended by adding at the end the following new section: The Secretary shall— establish a pilot program through which 5 State or local agencies conduct, in 5 States, point-of-use testing of illicit drugs for dangerous contaminants; establish metrics to evaluate the success of the pilot program in reducing drug overdose rates; and based on such metrics, conduct an annual evaluation of the pilot program and submit an annual report to the Congress containing the results of such evaluation. To carry out this section, there is authorized to be appropriated $5,000,000 for each of fiscal years 2019 through 2023. .
Connectionstraces to 2
Traces to 2 documents
1 reference not yet in our index
- 42 USC 247b–22
Citation graph
cites case law
Sec. 302
Surveillance and Testing of Opioids to Prevent Fentanyl Deaths
Cite42 USC 247b–22
Cites 3Cited by 0 across 0 sources